Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025
April 22 (Reuters) - Scienture Holdings Inc SCNX.O:
SCIENTURE ANNOUNCES MANUFACTURING AND SUPPLY CHAIN READINESS FOR ARBLITM, (LOSARTAN POTASSIUM) ORAL SUSPENSION, 10MG/ML FOR A TARGET PRODUCT LAUNCH IN JULY 2025.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.